hotspot -WSS

hotspot

author：knowledge 2025-09-27 09:47:12 - browse：36

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： STAT Summit: GSK CEO on pharma giant's new direction

knowledge

WSS

Senate committee scrutinizes Medicare Advantage brokers

Extensive review finds private equity owners jack up cost of care

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Judge denies Trump's request for new trial in E. Jean Carroll case

STAT Summit: Biotech founders on deal

2023 STAT Wunderkinds: get to know the winners

focus

hotspot

knowledge

Guidelines to prevent youth baseball injuries need more muscle

'CMA Fest' 2023: How to watch, who is performing and more

Medical records are filled with copy

STAT Readout Newsletter: Today's biggest biotech updates

Moonlake's readout produced a cash windfall. Risks remain

A new ‘biological computer' targets cancer while sparing healthy cells

Dobbs anniversary: the lost opportunity of abortion as health care

Researchers explore possible ties between long Covid, menopause

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare reduced heart disease by changing how it pays doctors

hotspot

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

First Opinion Podcast: Long Covid needs a new approach

The stock market has soared this year, but will it last? Experts weigh in

STAT Summit: How a Chicago ER doctor tackles gun violence

Judge denies Trump's request for new trial in E. Jean Carroll case

CEOs share strategies for surviving biotech slump

entertainment

hotspot

knowledge

focus